title: The involvement of VEGF in endothelial permeability: a target for anti-inflammatory therapy.
abstract: Many inflammatory mediators are known to contribute to increased vascular permeability during various phases of inflammation. Among these mediators, vascular endothelial growth factor (VEGF), also known as vascular permeability factor, plays an important role in vascular hyper-permeability, and several studies have demonstrated that modulation of VEGF function might contribute to a successful therapeutic approach to the treatment of inflammatory diseases. VEGF receptor monoclonal antibodies, glucocorticoids, leukotriene modifiers, cyclooxygenase-2 inhibitors and non-steroidal anti-inflammatory drugs have been studied for many years as VEGF-blocking drugs in inflammatory diseases in vitro and/or in vivo. The molecular and biological understanding of VEGF and preclinical or clinical trials of VEGF-blocking therapies raise hope that they may be useful as adjuncts to existing anti-inflammatory approaches in the regulation of inflammatory diseases.
authors.affiliation: Department of Internal Medicine, Research Center for Allergic Immune Diseases, Chonbuk National University Medical School, 634-18 Keumamdong, Jeonju 561-712, South Korea. leeyc@chonbuk.ac.kr
authors.forename: Yong C
authors.initials: YC
authors.lastname: Lee
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D029481:Bronchitis, Chronic / Q000188:drug therapy / Q000378:metabolism; D002199:Capillary Permeability / Q000187:drug effects* / Q000502:physiology; D016207:Cytokines / Q000494:pharmacology; D015195:Drug Design; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005786:Gene Expression Regulation / Q000187:drug effects; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D000860:Hypoxia / Q000235:genetics / Q000378:metabolism; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism; D008168:Lung / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000276:immunology / Q000378:metabolism*
chemical_list: D000318:Adrenergic beta-Agonists; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D016207:Cytokines; D004791:Enzyme Inhibitors; D006133:Growth Substances; D042461:Vascular Endothelial Growth Factor A; D011451:Prostaglandin-Endoperoxide Synthases; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor